Skip to main
ABSI

Absci Corp (ABSI) Stock Forecast & Price Target

Absci Corp (ABSI) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Absci Corp is demonstrating promising advancements in its clinical studies, particularly with the MAD study expected to yield significant initial efficacy data by the second half of 2026, indicating potential growth in novel therapeutics with ABS-201. The revised net present value (rNPV) of $1.6 billion reflects growing confidence in Absci's product pipeline, driven by preclinical evidence supporting the unique mechanism of action of ABS-201. Additionally, the strong interest in in-office procedures among potential users enhances the commercial outlook, positioning the company favorably as it approaches critical data releases.

Bears say

The financial analysis indicates several significant risks that may adversely affect Absci Corp's stock performance, including potential challenges related to partnerships, technology development, clinical trials, regulatory hurdles, commercial viability, legal issues, intellectual property, competition, and shareholder dilution. The lack of standard of care in endo, particularly for non-hormonal treatment options, may hinder the company's ability to effectively market its products. Additionally, with patients often opting for more permanent solutions due to high treatment burdens, the company's market for such biologics could face limitations in growth and acceptance.

Absci Corp (ABSI) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Absci Corp (ABSI) Forecast

Analysts have given Absci Corp (ABSI) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Absci Corp (ABSI) has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.98, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.98, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Absci Corp (ABSI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.